• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

    10/24/24 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEGN alert in real time by email

    SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review third-quarter 2024 results.

    During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter.

    Investors and other interested parties may join the live audio webcast of the call via this weblink.

    A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes.

    ABOUT LEGEND BIOTECH

    Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

    Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

    INVESTOR CONTACT:

    Jessie Yeung

    Tel: (732) 956-8271

    [email protected]

    PRESS CONTACT:

    Mary Ann Ondish

    Tel: (914) 552-4625

    [email protected]



    Primary Logo

    Get the next $LEGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will Legend Biotech hold its conference call for investors?

      Legend Biotech will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review its third-quarter 2024 results.

    • What will be discussed during the conference call on November 12, 2024?

      Senior leaders at Legend Biotech will provide an overview of the company's performance for the third quarter during the conference call.

    • How can investors participate in the Legend Biotech conference call?

      Investors and interested parties can join the live audio webcast of the call via the provided weblink in the announcement.

    • Where can one find the replay of the conference call after it concludes?

      A replay of the webcast and the earnings news release will be available approximately two hours after the call concludes under the Investor Relations section of Legend Biotech's website.

    • What is the focus of Legend Biotech as a biotechnology company?

      Legend Biotech is a global biotechnology company focused on developing advanced cell therapies, aiming to treat and potentially cure life-threatening diseases.

    Recent Analyst Ratings for
    $LEGN

    DatePrice TargetRatingAnalyst
    10/8/2024$86.00Buy
    Redburn Atlantic
    6/17/2024$88.00Buy
    Truist
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    5/23/2024$60.00Buy
    Deutsche Bank
    4/17/2024$65.00Sector Perform → Sector Outperform
    Scotiabank
    4/3/2024$82.00Overweight
    Cantor Fitzgerald
    3/13/2024$86.00Outperform
    Raymond James
    12/19/2023Sector Perform
    Scotiabank
    More analyst ratings

    $LEGN
    SEC Filings

    See more
    • SEC Form 144 filed by Legend Biotech Corporation

      144 - Legend Biotech Corp (0001801198) (Subject)

      6/24/25 10:05:41 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Legend Biotech Corporation

      6-K - Legend Biotech Corp (0001801198) (Filer)

      6/12/25 4:16:41 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Legend Biotech Corporation

      6-K - Legend Biotech Corp (0001801198) (Filer)

      6/6/25 4:01:50 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program. Investors and other interested parties may join the live webcast through this weblink or visit Legend Biotech's website under Events and Pre

      5/19/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

      CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia's TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biotech believes will provide financial runway into the second quarter of 2026 SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend

      5/13/25 7:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

      SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours

      4/29/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Legend Biotech with a new price target

      Redburn Atlantic initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $86.00

      10/8/24 7:29:11 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Legend Biotech with a new price target

      Truist initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $88.00

      6/17/24 7:33:12 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Legend Biotech with a new price target

      H.C. Wainwright reiterated coverage of Legend Biotech with a rating of Buy and set a new price target of $73.00 from $86.00 previously

      5/24/24 7:45:26 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care